Hostname: page-component-84b7d79bbc-5lx2p Total loading time: 0 Render date: 2024-07-30T13:39:06.244Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-Term Efficacy of Exposure and Ritual Prevention Therapy and Serotonergic Medications for Obsessive-Compulsive Disorder

Published online by Cambridge University Press:  07 November 2014

Elizabeth A. Hembree ,
David S. Riggs ,
Michael J. Kozak ,
Martin E. Franklin  and
Edna B. Foa
Get access Rights & Permissions [Opens in a new window]

Abstract

What is the long-term outcome of patients with obsessive-compulsive disorder (OCD) who are treatred with exposure and response (ritual) prevention (EX/RP) alone, serotonergic medications alone, or their combination? How is the long-term outcome of these patients affected by the discontinuation? Follow-up assessments were conducted with 62 patients treated for OCD an average of 17 months posttreatment (range: 6–43 months). Patients received one of three treatments: serotonergic medications (fluvoxamine or clomipramine), intensive behavior therapy involving EX/RP, or intensive EX/RP with concurrent antidepressant medication. At follow-up, no differences in OCD symptom severity were found among the three treatment groups. However, when current medication use was taken into consideration, differences among the three treatment groups emerged. Among patients who were medication-free at the time of follow-up assessment (n=37), those in the EX/RP-alone and EX/RP-with-medication groups had lower symptom severity ratings than those in the medication-only group on 4 out of 6 measures. There were no differences in OCD severity ratings among patients taking medications at follow-up (n=25). Although these findings are interpreted with caution due to the uncontrolled nature of the study, results suggested that long-term outcome may be superior following EX/RP than following serotonergic medications, after discontinuation. For patients who remain on medications, the treatment produced benefits equivalent to EX/RP.

Type
Original Research
Information
CNS Spectrums , Volume 8 , Issue 5: Psychosocial Treatment of Anxiety Disorders , May 2003 , pp. 363 - 371
Copyright
Copyright © Cambridge University Press 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Meyer, V. Modification of expectations in cases with obsessional rituals. Behav Res Ther. 1966;4:273–280.CrossRefGoogle ScholarPubMed
2.Foa, EB, Franklin, ME, Kozak, MJ. Psychosocial treatments for obsessive-compulsive disorder: literature review. In: Swinson, RP, Antony, MM, eds. Obsessive-Compulsive Disorder: Theory, Research, and Treatment. New York, NY: Guilford Press; 1998:258–276.Google Scholar
3.Franklin, ME, Foa, EB. Cognitive-behavioral treatment of obsessive-compulsive disorder. In: Nathan, PE, Gorman, JM, eds. A Guide to Treatments That Work. New York, NY: Oxford University Press; 1998:339–357.Google Scholar
4.Rauch, SL, Jenike, MA. Pharmacological treatment of obsessive-compulsive disorder. In: Nathan, PE, Gorman, JM, eds. A Guide to Treatments That Work. New York, NY: Oxford University Press; 1998:358–376.Google Scholar
5.Greist, J, Chouinard, G, DuBoff, E, et al.Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1995;52:289–295.CrossRefGoogle ScholarPubMed
6.Goodman, WK, Price, LH, Rasmussen, SA, Delgado, PL, Heninger, GR, Charney, DS. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison of fluvoxamine and placebo. Arch Gen Psychiatry. 1989;46:36–40.CrossRefGoogle Scholar
7.Wheadon, DE, Bushnell, WD, Steiner, M. A fixed-dose comparison of 20, 40 or 60 mg paroxetine to placebo in the treatment of OCD. Paper presented at: Annual Meeting of the American College of Neuropsychopharmaclogy; December 7-11, 1993; Honolulu, Hawaii.Google Scholar
8.Tollefson, G, Birkett, M, Koran, L, Genduso, L. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J Clin Psychiatry. 1994;55:69–78.Google ScholarPubMed
9.Foa, EB, Kozak, MJ. Psychological treatment for obsessive-compulsive disorder. In: Mavissakalian, MR, Prien, RF, eds. Long-term Treatment of Anxiety Disorders. Washington, DC: American Psychiatric Press; 1996:285–309.Google Scholar
10.Ravizza, L, Maina, G, Bogetto, F, Albert, U, Barzega, G, Bellino, S. Long-term treatment of obsessive-compulsive disorder. CNS Drugs. 1998;10:247–255.CrossRefGoogle Scholar
11.Zohar, J, Sasson, Y, Chopra, M, Amital, D, Iancu, I. Pharmacological treatment of obsessive-compulsive disorder: a review. In: Maj, M, Sartorius, N, Okasha, A, Zohar, J, eds. Obsessive-Compulsive Disorder. New York, NY: John Wiley & Sons, Inc.; 2000:43–92.CrossRefGoogle ScholarPubMed
12.Leonard, H, Swedo, S, Lenane, M, et al.A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry. 1991;48:922–927.CrossRefGoogle ScholarPubMed
13.Marks, IM, Lelliott, P, Basoglu, M, et al.Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. Br J Psychiatry. 1988;152:522–534.CrossRefGoogle ScholarPubMed
14.O'Sullivan, G, Noshirvani, H, Marks, I, Monteiro, W, Lelliott, P. Six-year follow-up after exposure and clomipramine therapy for obsessive-compulsive disorder. J Clin Psychiatry. 1991;52:150–155.Google ScholarPubMed
15.deHaan, E, van Oppen, P, van Balkom, AJLM, Spinhoven, P, Hoogduin, CAL, van Dyck, R. Prediction of outcome and early versus late improvement in OCD patients treated with cognitive behaviour therapy and pharmacotherapy. Acta Psychiatr Scand. 1997;96:354–362.CrossRefGoogle Scholar
16.Cottraux, J, Mollard, E, Bouvard, M, Marks, I. Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year follow-up. Psychiatry Res. 1993;49:63–75.CrossRefGoogle ScholarPubMed
17.Baer, L, Ricciardi, J, Keuthen, N, et al.Discontinuing obsessive-compulsive disorder medication with behavior therapy. Am J Psychiatry. 1994;151:1842.Google ScholarPubMed
18.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed rev. Washington, DC: American Psychiatric Association; 1987.Google Scholar
19.Goodman, WK, Price, LH, Rasmussen, SA, et al.The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS): past development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006–1016.CrossRefGoogle Scholar
20.Foa, EB, Grayson, JB, Steketee, GS, et al.Success and failure in the behavioral treatment of obsessive-compulsives. J Consult Clin Psychol. 1983;51:287–297.CrossRefGoogle ScholarPubMed
21.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.CrossRefGoogle ScholarPubMed
22.Hedlund, J, Vieweg, B. The Hamilton Rating Scale for Depression: a comprehensive review. J Operating Psychiatry. 1979;10:149–165.Google Scholar
23.Foa, EB, Kozak, MJ, Goodman, WK, Hollander, E, Jenike, MA, Rasmussen, SA. DSM-IV field trial: obsessive-compulsive disorder. Am J Psychiatry. 1995;152:90–94.Google ScholarPubMed
24.Pato, MT, Zohar-Kadouch, R, Zohar, J, Murphy, DL. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry. 1988;145:1521–1525.Google ScholarPubMed